Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Tenpoint Therapeutics","sponsor":"SparingVision","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SparingVision Sells Ex Vivo GIRK Technology to Tenpoint Therapeutics","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2023","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical"},{"orgOrder":0,"company":"Tenpoint Therapeutics","sponsor":"British Patient Capital","pharmaFlowCategory":"D","amount":"$70.0 million","upfrontCash":"Undisclosed","newsHeadline":"Tenpoint Therapeutics Launches with $70 Million Series A Financing to Reverse Vision Loss Through Engineered Cell-Based Therapeutics and In Vivo Reprogramming","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Discovery Platform","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2023","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Discovery Platform"}]

    Find Clinical Drug Pipeline Developments & Deals by Tenpoint Therapeutics

    Menu

    Tenpoint Therapeutics

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Tenpoint Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              SparingVision Sells Ex Vivo GIRK Technology to Tenpoint Therapeutics

              Details:

              Through the divestment, Tenpoint has acquired SparingVision's ex vivo GIRK technology. SparingVision will remain focused on in vivo genomic medicines, with SPVN20, a GIRK-based gene therapy candidate.

              Lead Product(s): SPVN20

              Therapeutic Area: Genetic Disease Product Name: SPVN20

              Highest Development Status: Preclinical Product Type: Cell and Gene therapy

              Recipient: SparingVision

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Divestment July 12, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Tenpoint Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Tenpoint Therapeutics Launches with $70 Million Series A Financing to Reverse Vision Loss Through Engineered Cell-Based Therapeutics and In Vivo Reprogramming

              Details:

              Tenpoint will use the net proceeds to develop its regenerative medicine platform to replace multiple cell types lost to inherited and age-related conditions.

              Lead Product(s): Undisclosed

              Therapeutic Area: Ophthalmology Product Name: Undisclosed

              Highest Development Status: Discovery Platform Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: British Patient Capital

              Deal Size: $70.0 million Upfront Cash: Undisclosed

              Deal Type: Series A Financing July 12, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              Temad- We think of world-class quality.
              Post Enquiry
              POST ENQUIRY